Hanna Bernstine
Papers
1
Total Citations
37
H-Index
1
About
Hanna Bernstine is a leading researcher in nuclear medicine and oncology, with a focus on theranostics—the integration of diagnostic imaging and targeted radionuclide therapy. Her major contributions center on advancing treatment for prostate cancer, particularly through the use of prostate-specific membrane antigen (PSMA)-targeted radionuclides. Her most cited work, a single-arm Phase 1 trial published in 2022, demonstrated the safety and feasibility of neoadjuvant 177Lu-PSMA-I&T radionuclide treatment in high-risk prostate cancer patients before radical prostatectomy. This study, with 37 citations, has opened new avenues for combining systemic radionuclide therapy with surgery, potentially improving outcomes for aggressive disease. Bernstine’s research bridges preclinical innovation and clinical application, offering a personalized approach to cancer care. Her work is widely recognized for its translational impact, influencing protocols in nuclear oncology and urology. By pioneering theranostic strategies, she has contributed to a paradigm shift in how high-risk prostate cancer is managed, making her a key figure in the field.
Research Focus
Key Achievements
Top Papers
- 1